LAS VEGAS--(BUSINESS WIRE)--May 2, 2006--Samaritan Pharmaceuticals (AMEX:LIV - News): Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it completed a Phase II Stage 1 (10 day monotherapy study) with 34 patients in which SP01A was being evaluated as an adjunct therapy for treatment-experienced HIV patients who are failing on their current anti-viral therapy. Samaritan also notes it has started enrolling for its Stage 2 (28 day monotherapy trial) and numerous Stage 1 evaluates are rolling over to Stage 2 which will count toward the 60 evaluates Samaritan intends to enroll for the Phase II Stage 2.
